Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NEOPANC-01 is a window of opportunity study looking to assess gene expression in patients with resectable pancreatic cancer. It aims to evaluate the utility of whole transcriptome RNA sequencing as a potential biomarker for future window-of-opportunity trials that will assess existing and/or new treatments for pancreatic cancer. An understanding of the variability in the transcriptomic signature between biopsies will also inform power calculations for future studies. Lastly, the data generated will be available for use as historical controls for future studies. 2 sets of biopsy samples will be taken throughout the trial. Firstly during an endoscopic ultrasound procedure and then again, up to 6 weeks later, during the patients surgery to remove the cancer. Once all patients have been recruited, the mRNA from the samples will be sequenced and analysed. Further samples will also be taken at the same time points for storage into a biobank and for use in future research. This is a single site study opening at the Churchill Hospital looking to recruit 10 patients over 18 months.

Similar stories

AVID-CC trial opens to recruitment!

OCTRU

The AVID-CC trial has received OCTRU Green Light approval and is now open to recruitment!

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.